Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has closed a $17 million seed financing, led by Sutter Hill Ventures with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan.
The company also announced that Keith Loebner, Ph.D. has been appointed to the company’s Board of Directors and that Karl Sylvester, M.D., Uri Alon, Ph.D., and Wendy B. Young, Ph.D. have been appointed as advisors to the company.
Read also – [Funding News] Crescendo Secures $50M in Funding
“We started Integrated Biosciences to make real progress toward achieving healthier human aging,” said Felix Wong, Ph.D., Co-Founder and CEO. “The new capital will significantly advance our efforts toward this ambitious goal by enabling us to scale up our synthetic biology and AI platform while investing in the clinical development of our small-molecule portfolio. Our world-class syndicate, led by Sutter Hill Ventures, represents visionary investors who appreciate our scientific progress and understand that we are an entirely different type of company, in terms of both our mission and our technology.”
Founded in September 2022, Integrated Biosciences has consistently reported on its drug discovery engine in leading journals, including Nature, Nature Aging, and Cell Systems. Integrated Biosciences differentiates itself by using synthetic biology and optogenetics to control and generate highly specific data across different cellular phenotypes. This capability enables the company to identify new targets, modulate any biological pathway of interest, and deploy its proprietary AI platform to discover precise and novel small-molecule drug candidates. Having pioneered the first AI-driven discovery of a structural class of antibiotics last year, the company is now developing a portfolio of preclinical-stage assets to treat multiple age-related diseases.
“Our world-class syndicate, led by Sutter Hill Ventures, represents visionary investors who appreciate our scientific progress and understand that we are an entirely different type of company, in terms of both our mission and our technology”, Felix Wong, CEO of Integrated Biosciences said.
Integrated Biosciences plans to use the new funding to accelerate the development of its drug pipeline, further develop its platform, and advance its commercialization efforts. The company’s approach of targeting fundamental, age-related pathways on the phenotypic level enables it to develop assets that have broad applicability to treating diverse diseases. Building on its strength in rapidly discovering and developing assets, the company is pursuing a multi-asset business model in which assets will be advanced through a combination of company-led development and co-development partnerships.
About Integrated Biosciences
Integrated Biosciences is a biotechnology company pioneering novel approaches that combine synthetic biology and AI-driven small-molecule drug discovery to produce next-generation therapeutics targeting age-related diseases.
